Skip to main
AAPG
AAPG logo

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group has exhibited strong commercial viability, with olverembatinib generating RMB 217.4 million (approximately US$30.3 million) in sales during the first half of 2025, marking a significant 93% year-over-year increase. The company's expansion in formulary coverage to over 295 hospitals, along with a 17% increase in DTP pharmacies and hospitals onboarded, highlights its growing market presence and accessibility for its innovative therapies. Furthermore, the favorable environment for mid-cap biotech firms, evidenced by a 58% year-to-date gain in a China Biotech ETF, underscores the optimistic investor sentiment towards the sector, positioning Ascentage Pharma favorably within this landscape.

Bears say

Ascentage Pharma Group faces multiple challenges that contribute to a negative outlook, primarily due to the ongoing volume-based procurement program which, although initially targeting generics, is creating downward pressure on margins and may hinder revenue growth for innovative therapies. Additionally, the company has experienced setbacks in clinical trials, notably the failure to meet primary endpoints, which diminishes its global expansion potential and could harm its competitive positioning in the market. Furthermore, slower adoption of its therapy Olverembatinib in China, coupled with the limitations in differentiating its products from established competitors, raises further concerns about the company’s future revenue prospects and overall financial stability.

AAPG has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Strong Buy based on their latest research and market trends.

According to 3 analysts, AAPG has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.